Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 14/20 | 0.32 |
| ▸ | HTR7 | P34969 | 13/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.32 |
| ▸ | DRD2 | P14416 | 9/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31479627 | 0.95 | HTR2A (0.34) | HTR2AHTR7KCNH2DRD2HCRTR1 | |
| SCHEMBL31479316 | 0.95 | HTR2A (0.34) | HTR2AHTR7KCNH2DRD2HCRTR1 | |
| SCHEMBL31479175 | 0.95 | HCRTR1 (0.34) | HTR2AHTR7KCNH2DRD2HCRTR1 | |
| SCHEMBL31479721 | 0.95 | HCRTR1 (0.34) | HTR2AHTR7KCNH2DRD2HCRTR1 | |
| SCHEMBL31479636 | 0.92 | HTR2A (0.32) | HTR2AHTR7KCNH2DRD2HCRTR1 | |
| SCHEMBL31479576 | 0.92 | HTR2A (0.32) | HTR2AHTR7KCNH2DRD2HCRTR1 | |
| SCHEMBL31479697 | 0.90 | HTR2A (0.34) | HTR2AHTR7KCNH2DRD2 | |
| SCHEMBL31479416 | 0.90 | HTR2A (0.34) | HTR2AHTR7KCNH2DRD2 | |
| SCHEMBL31479562 | 0.90 | PLK1 (0.34) | MAPK14 | |
| SCHEMBL31479235 | 0.90 | PLK1 (0.34) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067111-A1 | MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION | 苏州必扬医药科技有限公司 | 2025-04-03 | — | — | WO | disclosed |